Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Intervalo de año de publicación
1.
Prenat Diagn ; 44(8): 996-998, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38666792

RESUMEN

We present a case of fetal akinesia deformation sequence due to nemaline myopathy (NM). In addition to the muscle manifestations, prenatal observations included an enlarged subarachnoid space and delayed cortical development. Trio whole-exome sequencing revealed a de novo novel pathogenic variant in the ACTA1 gene, which encodes skeletal muscle alpha-actin. Our findings suggest that brain abnormalities can occur prenatally in NM and support the potential role of skeletal muscle alpha-actin in the central nervous system.


Asunto(s)
Actinas , Miopatías Nemalínicas , Humanos , Femenino , Actinas/genética , Embarazo , Adulto , Miopatías Nemalínicas/genética , Secuenciación del Exoma , Ultrasonografía Prenatal , Malformaciones del Desarrollo Cortical/genética , Malformaciones del Desarrollo Cortical/diagnóstico por imagen , Artrogriposis
2.
JAMA ; 329(7): 542-550, 2023 02 21.
Artículo en Inglés | MEDLINE | ID: mdl-36809321

RESUMEN

Importance: Aspirin reduces the incidence of preterm preeclampsia by 62% in pregnant individuals at high risk of preeclampsia. However, aspirin might be associated with an increased risk of peripartum bleeding, which could be mitigated by discontinuing aspirin before term (37 weeks of gestation) and by an accurate selection of individuals at higher risk of preeclampsia in the first trimester of pregnancy. Objective: To determine whether aspirin discontinuation in pregnant individuals with normal soluble fms-like tyrosine kinase-1 to placental growth factor (sFlt-1:PlGF) ratio between 24 and 28 weeks of gestation was noninferior to aspirin continuation to prevent preterm preeclampsia. Design, Setting, and Participants: Multicenter, open-label, randomized, phase 3, noninferiority trial conducted in 9 maternity hospitals across Spain. Pregnant individuals (n = 968) at high risk of preeclampsia during the first-trimester screening and an sFlt-1:PlGF ratio of 38 or less at 24 to 28 weeks of gestation were recruited between August 20, 2019, and September 15, 2021; of those, 936 were analyzed (intervention: n = 473; control: n = 463). Follow-up was until delivery for all participants. Interventions: Enrolled patients were randomly assigned in a 1:1 ratio to aspirin discontinuation (intervention group) or aspirin continuation until 36 weeks of gestation (control group). Main Outcomes and Measures: Noninferiority was met if the higher 95% CI for the difference in preterm preeclampsia incidences between groups was less than 1.9%. Results: Among the 936 participants, the mean (SD) age was 32.4 (5.8) years; 3.4% were Black and 93% were White. The incidence of preterm preeclampsia was 1.48% (7/473) in the intervention group and 1.73% (8/463) in the control group (absolute difference, -0.25% [95% CI, -1.86% to 1.36%]), indicating noninferiority. Conclusions and Relevance: Aspirin discontinuation at 24 to 28 weeks of gestation was noninferior to aspirin continuation for preventing preterm preeclampsia in pregnant individuals at high risk of preeclampsia and a normal sFlt-1:PlGF ratio. Trial Registration: ClinicalTrials.gov Identifier: NCT03741179 and ClinicalTrialsRegister.eu Identifier: 2018-000811-26.


Asunto(s)
Aspirina , Preeclampsia , Nacimiento Prematuro , Privación de Tratamiento , Adulto , Femenino , Humanos , Recién Nacido , Embarazo , Aspirina/efectos adversos , Aspirina/uso terapéutico , Biomarcadores/sangre , Hemorragia/sangre , Hemorragia/inducido químicamente , Hemorragia/prevención & control , Periodo Periparto , Factor de Crecimiento Placentario/sangre , Preeclampsia/sangre , Preeclampsia/prevención & control , Complicaciones del Embarazo/sangre , Complicaciones del Embarazo/inducido químicamente , Complicaciones del Embarazo/prevención & control , Primer Trimestre del Embarazo , Nacimiento Prematuro/sangre , Nacimiento Prematuro/prevención & control , Receptor 1 de Factores de Crecimiento Endotelial Vascular/sangre
3.
BMC Pregnancy Childbirth ; 22(1): 669, 2022 Aug 30.
Artículo en Inglés | MEDLINE | ID: mdl-36042432

RESUMEN

OBJECTIVES: To develop gestational age-based reference ranges for cervical length in triplet pregnancies. The secondary objective was to assess the performance of cervical length measured between 18 and 20 + 6 days for the prediction of preterm delivery before 28 and 32 weeks, respectively. METHODS: Observational retrospective study of triplet pregnancies in three Spanish tertiary-care hospitals between 2001 and 2019. Cervical length measurements were consecutively obtained between 15 and 34 weeks of gestation. Pregnancies undergoing multifetal reduction or fetal surgery were excluded. RESULTS: Two hundred and six triplet pregnancies were included in the final analysis. There was a quadratic decrease in cervical length with gestational age. The median and fifth centiles for cervical length at 20 weeks were 35 and 13 mm. In the prediction of preterm birth < 28 weeks, for a false positive rate of 5%, and 10%, the detection rates were 40.9%, and 40.9%, respectively, and the prediction of preterm birth < 32 weeks, 22.0% and 26.0%, respectively. CONCLUSIONS: In triplet pregnancies, cervical length decreases with gestational age. The performance of cervical length at 18-20 + 6 in screening for preterm birth before 28 and 32 weeks is poor.


Asunto(s)
Embarazo Triple , Nacimiento Prematuro , Medición de Longitud Cervical , Cuello del Útero/diagnóstico por imagen , Femenino , Edad Gestacional , Humanos , Recién Nacido , Embarazo , Nacimiento Prematuro/diagnóstico , Nacimiento Prematuro/epidemiología , Nacimiento Prematuro/prevención & control , Valores de Referencia , Estudios Retrospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA